BRD2 and glioblastoma: Since the MES gene signature is associated with therapeutic resistance in GBM (31), we assessed whether depletion of BRD2 sensitizes GSCs to temozolomide (TMZ) and found that BRD2 knockdown cells were more sensitive to TMZ compared to control GSCs (Figure 4E and S3F).